Eli Lilly: The Right Long-Term Strategy
Source: SeekingAlpha
2025-12-13 04:33:24 ET
Introduction
Eli Lilly ( LLY ) has generated their Keytruda/Humira moment. A generation-defining medicine that in fact owns a duopoly, for the time being, with Novo Nordisk ( NVO ). Cash flows for the next few years will be immense but will become a double-edged sword in time. The question will be how Lilly can reinvest and diversify away from relying on diabetes and obesity meds while they generate the cash to do so. Will they finally become a high-yielding biopharma like Amgen ( AMGN ), Bristol Myers Squibb ( BMY ), or Pfizer ( PFE ), or will they become a secular growth seeker like AstraZeneca?...
Read the full article on Seeking Alpha
For further details see:
Eli Lilly: The Right Long-Term Strategy
Chugai Pharmaceutical
NASDAQ: CHGCF
CHGCF Trading
1.92% G/L:
$61.2525 Last:
411 Volume:
$61.2525 Open:
